Related Experiment Videos
Comparative evaluation of cefmenoxime versus cefoxitin in serious infections
Abstract:
Fifty-nine patients with serious infections were assigned at random in a two-to-one ratio to receive either cefmenoxime or cefoxitin given intravenously in a dosage of 0.5 to 2.0 g every six hours. Of 44 patients evaluable for efficacy, eight had concomitant bacteremia and all but 10 had serious underlying disease. The average duration of therapy was seven days. All patients with skin and soft tissue infections were cured after treatment with either antibiotic. Cefmenoxime achieved clinical and bacteriologic cures in 92 and 83 percent, respectively, of 12 patients with pneumonia and in 100 and 82 percent of 11 patients with urinary tract infections. Cefoxitin therapy resulted in clinical and bacteriologic cures in all four patients with pneumonia. Among 10 patients with urinary tract infection, respective cure rates were 90 and 50 percent. Both antibiotics were well tolerated. One cefmenoxime-treated patient discontinued treatment because of a rash.
Insights
Cefmenoxime and cefoxitin effectively treated serious infections, including pneumonia and urinary tract infections, with comparable clinical outcomes. Both antibiotics were well-tolerated, demonstrating their therapeutic potential in managing severe bacterial infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Serious bacterial infections pose significant therapeutic challenges.
- Intravenous antibiotics are crucial for managing severe infections.
- Cefmenoxime and cefoxitin are cephalosporin antibiotics with broad-spectrum activity.
Purpose of the Study:
- To compare the efficacy and safety of cefmenoxime versus cefoxitin in treating serious infections.
- To evaluate clinical and bacteriologic cure rates for specific infection types.
Main Methods:
- A randomized, two-to-one ratio study involving 59 patients with serious infections.
- Patients received either cefmenoxime or cefoxitin intravenously (0.5-2.0 g every six hours) for an average of seven days.
- Efficacy was assessed in 44 evaluable patients, including those with bacteremia and serious underlying conditions.
Main Results:
- All patients with skin and soft tissue infections achieved cure with either antibiotic.
- Cefmenoxime demonstrated high clinical (92%) and bacteriologic (83%) cure rates in pneumonia, and 100% clinical and 82% bacteriologic cures in urinary tract infections.
- Cefoxitin achieved 100% clinical cure in pneumonia and 90% clinical cure in urinary tract infections, with a 50% bacteriologic cure rate in UTIs.
- Both antibiotics were generally well-tolerated, with one cefmenoxime patient discontinuing due to rash.
Conclusions:
- Cefmenoxime and cefoxitin show comparable efficacy in treating serious infections like pneumonia and urinary tract infections.
- Both intravenous antibiotics are safe and effective options for managing severe bacterial infections.
- Further research may explore specific patient populations and resistance patterns.